These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7715890)

  • 1. Assessment of myocardial viability: where are we?
    McKillop JH
    Nucl Med Commun; 1994 Dec; 15(12):935-6. PubMed ID: 7715890
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography.
    Sandler MP; Videlefsky S; Delbeke D; Patton JA; Meyerowitz C; Martin WH; Ohana I
    J Am Coll Cardiol; 1995 Oct; 26(4):870-8. PubMed ID: 7560611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: an alternative for determining myocardial viability.
    Sandler MP; Patton JA
    J Nucl Cardiol; 1996; 3(4):342-9. PubMed ID: 8799254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed recovery of hibernating myocardium after surgical revascularization: implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability.
    Bax JJ; Poldermans D; Visser FC; Elhendy A; Boersma E; Cornel JH; Fiorettri PM; Visser CA
    J Nucl Cardiol; 1999; 6(6):685-7. PubMed ID: 10608600
    [No Abstract]   [Full Text] [Related]  

  • 5. Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation.
    Beller GA
    J Nucl Cardiol; 1997; 4(2 Pt 2):S152-7. PubMed ID: 9115077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of hibernating myocardium: a comparison between dobutamine echocardiography and study of perfusion and metabolism in patients with severe left ventricular dysfunction.
    Mariani MA; Palagi C; Donatelli F; Mengozzi G; Biadi O; Vanoli G; Landoni C; Paolini G; Lucignani G; Fazio F
    Am J Card Imaging; 1995 Jan; 9(1):1-8. PubMed ID: 7894227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thallium-201 uptake in lung cancer.
    Chin BB; Zukerberg BW; Buchpiguel C; Alavi A
    J Nucl Med; 1995 Aug; 36(8):1514-9. PubMed ID: 7629600
    [No Abstract]   [Full Text] [Related]  

  • 8. Present assessment of myocardial viability by nuclear imaging.
    Saha GB; MacIntyre WJ; Brunken RC; Go RT; Raja S; Wong CO; Chen EQ
    Semin Nucl Med; 1996 Oct; 26(4):315-35. PubMed ID: 8916320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dobutamine echocardiography, dobutamine sestamibi, and rest-redistribution thallium-201 single-photon emission computed tomography for determining contractile reserve and myocardial ischemia in ischemic cardiomyopathy.
    Amanullah AM; Chaudhry FA; Heo J; Galatro K; Dourdoufis P; Brozena S; Narula J; Iskandrian AE
    Am J Cardiol; 1999 Sep; 84(6):626-31. PubMed ID: 10498129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography.
    Bax JJ; Cornel JH; Visser FC; Fioretti PM; van Lingen A; Reijs AE; Boersma E; Teule GJ; Visser CA
    J Am Coll Cardiol; 1996 Sep; 28(3):558-64. PubMed ID: 8772739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial viability. What does it mean and how do we measure it?
    Gould KL
    Circulation; 1991 Jan; 83(1):333-5. PubMed ID: 1984890
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of SPECT using technetium-99m agents and thallium-201 and PET for the assessment of myocardial perfusion and viability.
    Berman DS; Kiat H; Van Train KF; Friedman J; Garcia EV; Maddahi J
    Am J Cardiol; 1990 Oct; 66(13):72E-79E. PubMed ID: 2145750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization.
    Baer FM; Voth E; Deutsch HJ; Schneider CA; Horst M; de Vivie ER; Schicha H; Erdmann E; Sechtem U
    J Am Coll Cardiol; 1996 Jul; 28(1):60-9. PubMed ID: 8752795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues.
    Dilsizian V; Bacharach SL; Khin MM; Smith MF
    J Nucl Cardiol; 2001; 8(1):75-88. PubMed ID: 11182712
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of reversible myocardial tissue injury (stunning) after thrombolytic therapy using radioisotope imaging techniques.
    Parodi O
    J Nucl Biol Med (1991); 1991; 35(2):63-5. PubMed ID: 1834191
    [No Abstract]   [Full Text] [Related]  

  • 16. Prediction of left ventricular functional recovery by dobutamine echocardiography, F-18 deoxyglucose or 99mTc sestamibi nuclear imaging in patients with chronic myocardial infarction.
    Lund GK; Freyhoff J; Schwaiger M; Lübeck M; Lund CH; Buchert R; Sheehan FH; Meinertz T; Nienaber CA
    Cardiology; 2002; 98(4):202-9. PubMed ID: 12566650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The noninvasive assessment of myocardial viability.
    Ragosta M; Beller GA
    Clin Cardiol; 1993 Jul; 16(7):531-8. PubMed ID: 8348761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of viability assessment in chronic ischemic heart failure.
    Calhoun WB; Mills RM; Drane WE
    Clin Cardiol; 1996 May; 19(5):367-9. PubMed ID: 8723594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue characterization in nuclear oncology: its time has come.
    Lamki LM
    J Nucl Med; 1995 Feb; 36(2):207-10. PubMed ID: 7830115
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease.
    vom Dahl J; Altehoefer C; Sheehan FH; Buechin P; Schulz G; Schwarz ER; Koch KC; Uebis R; Messmer BJ; Buell U; Hanrath P
    J Nucl Med; 1997 May; 38(5):742-8. PubMed ID: 9170439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.